The brain cancer diagnostics market was valued at US$ 844.63 million in 2021 and is projected to reach US$ 2,476.14 million by 2028; it is expected to grow at a CAGR of 16.6 % from 2021 to 2028.
The growth of the brain cancer diagnostics market is attributed to factors such as an increase in the prevalence of brain cancer worldwide and technological advancements in brain cancer diagnostics. However, the market is likely to get impacted by the high cost involved in brain cancer diagnostics.
Brain cancer is caused due to extracellular growth of the cells in the brain that causes tumors.Tumors can be primary brain tumors and secondary brain tumors.
Primary brain tumors are formed in the brain and do not spread to other body parts, whereas secondary tumors, also known as metastases, are those cancers that began in another part of the body. Symptoms of brain cancer include headaches, nausea, fatigue, drowsiness, and many more. Cancer of the brain and nervous system is the tenth highest cause of mortality in men and women.According to the American Society of Clinical Oncology (ASCO), in 2021, around 24,530 adults (13,840 men and 10,690 women) are likely to be diagnosed with primary cancerous tumors of the brain and spinal cord in the US.
In a person’s lifetime, the chances of having this form of tumor are lesser than 1%.Most primary central nervous system (CNS) malignancies are brain tumors, which account for 85% to 90% of all cases.
Brain tumors can be fatal, have a severe impact on the quality of life, and ultimately turn a patient’s and their family’s lives. Similarly, Cancer Research UK estimated that around 12,100 new cases of brain, other CNS, and intracranial tumors are diagnosed in the UK each year, which makes it around 33 cases per day (2015-2017).Brain tumors and other central nervous systems and intracranial tumors are the ninth most common malignancies in the UK, accounting for 3% of all new cancer cases (2017).
Also, it is the eighth most common cancer in females in the UK with around 6,100 new cases in 2017.In males in the UK, brain, other CNS, and intracranial tumors are the eleventh most common cancer, with about 5,800 new cases in 2017.
Incidence rates for brain tumors are projected to rise by 6% in the UK between 2014 and 2035, to 22 cases per 100,000 people by 2035.
The COVID-19 pandemic has become the most significant challenge across the world.It has disturbed various trades and businesses across the world.
As a result of the COVID-19 pandemic, many diagnostic departments have experienced a rapid decline in imaging case volumes.This has important implications on the short-term and long-term economic stability of neurological procedures across all healthcare practice settings.
Due to lockdowns imposed by governments across the world, many neurological procedures were delayed, and supply chain restrictions limited the availability of resources needed to deliver brain cancer diagnostic services.
Based on diagnostic type, the brain cancer diagnostics market is segmented into imaging test, lumbar puncture, biopsy, molecular testing, and others.The imaging test segment held the largest share of the market in 2021, and the molecular testing segment is anticipated to register the highest CAGR in the market during the forecast period.
The imaging test segment is further classified into magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET). Based on cancer type, the brain cancer diagnostics market is segmented into Astrocytomas, Glioblastoma Multiforme, Ependymomas, and others.The Glioblastoma Multiforme segment held the largest share of the market in 2021, and the same segment is estimated to register the highest CAGR in the market during the forecast period.
Growth of the Glioblastoma Multiforme segment is attributed to the increased prevalence of this type of brain cancer.
Based on end user, the brain cancer diagnostics market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and others.The hospitals segment held the largest share of the market in 2021.
The specialty clinics segment is estimated to register the highest CAGR in the market during the forecast period. The American Society of Clinical Oncology, American Association of Neurological Surgeons, National Health Service, The Food and Drug Administration, The World Health Organization, Centers for Disease Control and Prevention, and Brain Tumor Registry of various countries are among the major primary and secondary sources referred to while preparing this report.
Our reports have been used by over 10K customers, including:
Anaplastic Astrocytoma (Oncology) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma - Drugs In Development, 2021, provides an overview of the Anaplastic Astrocytoma (Oncology) pipeline landscape.Anaplastic astrocytoma is a...
The global flow cytometry market size is projected to reach USD 6.3 billion by 2026 from USD 4.3 billion in 2021, growing at a CAGR of 8.1% from 2020 to 2026. The key factors driving the growth of this market include technological advancements in flow cytometers, the increasing adoption of flow cytometry in research and clinical trials, growing...
The global nuclear medicine market is projected to reach USD 7.5 billion by 2026 from USD 4.8billion in 2021, at a CAGR of 9.0% during the forecast period. Growth in the nuclear medicine market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the...
The apheresis market was valued at approximately USD 1,639 million in 2020, and it is expected to witness a revenue of USD 2580 million in 2026, with a CAGR of 7.85% over the forecast period, 2021-2026. The apheresis market is expected to be positively impacted during the COVID-19 pandemic owing to the extensive application of plasma...
Executive Summary Global Radiotherapy Market was valued at USD 7987.01 Million in the year 2020. Increasing healthcare expenditure on the back of growing disposable income, rapid technological advancements along with high prevalence of cancer is expected to drive the radiotherapy market significantly. Further, expanding...
The ablation technology market is projected to reach USD 8.1 Billion by 2026 from USD 5.2 Billion in 2021, at a CAGR of 9.3% during the forecast period. The growing elderly population has also driven the incidence of target conditions and contributed to the demand for effective treatment. However, the reuse and reprocessing of devices in developed...
histopathology services market was valued at US$ 35,187.90 million by 2028 from US$ 23,890.44 million in 2021; it is expected to grow at a CAGR of 5.7% from 2021 to 2028. Factors such as rising demand for biologics and increasing prevalence of chronic diseases are driving the growth of the histopathology services market. However, limitations...
214 pages •
By Asia Market Information & Development Company
• Aug 2021
China’s demand for Anti-Tumor Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...
The global esoteric testing market is projected to reach USD 36.3 billion by 2026 from USD 21.0 billion in 2021, at a CAGR of 11.6% during the forecast period. Market growth is largely driven by the rising incidence of chronic and infectious diseases, increasing use of esoteric DNA sequencing technologies in precision medicine, early diagnosis...
The global radiotherapy market is valued at USD 5.9 billion in 2021 and is expected to reach USD 7.3 billion by 2026, at a CAGR of 4.2% during the forecast period. The growth of this market is primarily driven by the rising burden of target diseases and increasing investments, funds, and grants for the development of novel products. Additionally,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.